AIDS 2008 – Mexico City 3-8 August 2008 - XVII Internationnal AIDS Conference

Late Breaker Track C	THAC05

Organiser:

Type:

Oral Abstract Session

Back

Venue:

SR 11 (1400)

Interpretation:

None

Time:

16:30 - 18:00, 07.08.2008

Code:

THAC05

Co-Chairs:

Javier Cabral, Mexico
Kevin De Cock, Switzerland

Presentations in this session:

16:30
THAC0501
Abstract
Powerpoint (152 KB) The protective effect of male circumcision is sustained for at least 42 months: results from the Kisumu, Kenya Trial
Presented by Robert C. Bailey, United States
R.C. Bailey¹, S. Moses², C.B. Parker³, K. Agot⁴, I. Maclean⁵, J.N. Krieger⁶, C.F. Williams⁷, J.O. Ndinya-Achola⁸
¹University of Illinois at Chicago, School of Public Health, Chicago, United States, ²University of Manitoba, Community Health Sciences and Medicine, Winnipeg, Canada, ³RTI International, Statistics and Epidemiology Division, RTP, North Carolina, United States, ⁴UNIM Clinic and University of Manitoba, Community Health Sciences and Medicine, Winnipeg, Canada, ⁵University of Manitoba, Department of Medical Microbiology, Winnipeg, Canada, ⁶University of Washington School of Medicine, Department of Urology, Seattle, Washington, United States, ⁷National Institute of Allergy and Infectious Disease, Division of AIDS, Bethesda, MD, United States, ⁸University of Nairobi, Department of Medical Microbiology, Nairobi, Kenya

16:45
THAC0502
Abstract Effect of male circumcision on human papilloma virus, neisseria gonorrhoeae and trichomonas vaginalis infections in men: results from a randomized controlled trial
Presented by Dirk Taljaard, South Africa
B. Auvert¹, J. Sobngwi –Tambekou¹, A. Puren², M. Nieuwoudt², E. Cutler², P. Lissouba¹, D. Taljaard³
¹INSERM, Paris, France, ²NICD, Johannesburg, South Africa, ³Progressus, Johannesburg, South Africa

17:00
THAC0503
Abstract Complete protection against repeated vaginal SHIV exposures in macaques by a combination emtricitabine and tenofovir topical gel
Presented by Walid Heneine, United States
U.M. Parikh¹, S. Sharma¹, M.-E. Cong¹, H. Jia¹, A. Martin¹, C.-P. Pau¹, D. Hanson¹, J. Smith¹, J.G. Garcia-Lerma¹, F.J. Novembre², R.A. Otten¹, T. Folks¹, W. Heneine¹
¹Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Atlanta, United States, ²Emory University, Yerkes Primate Center, Atlanta, United States

17:15
THAC0505
Abstract Can unsafe sex be safe? Review of sexual transmissibility of HIV-1 according to viral load, HAART, and sexually transmitted infections
Presented by Suzanna Attia, Switzerland
S. Attia¹, M. Egger¹, N. Low¹
¹University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland

17:15
THAC0504
Abstract Pregnancy and HIV transmission among HIV discordant couples in a clinical trial in Kisumu, Kenya
Presented by Sara Brubaker (TBC)
S. Brubaker¹, E. Bukusi², J. Odoyo³, J. Achando³, A. Okumu³, C. Cohen¹
¹University of California San Francisco, Obstetrics, Gynecology and Reproductive Sciences, San Francisco, United States, ²Kenya Medical Research Institute, Center for Microbiology Research, Nairobi, Kenya, ³Kenya Medical Research Institute, Center for Microbiology Research, Kisumu, Kenya (TBC)

17:30
THAC0506
Abstract
Powerpoint (402 KB) Integrating counseling and testing for HIV into FP services in Kenya is feasible, acceptable and effective in increasing VCT uptake and improving the quality of care
Presented by Robert Ayisi, Kenya
R. Ayisi¹, W. Liambila²
¹NASCOP, HIV/AIDS, Nairobi, Kenya, ²Population Council, Nairobi, Kenya

Rapporteur report

Track C report by Patrick Sullivan

The latebreaker oral abstract presentations contained important new information about male circumcision and preclinical microbicide development, as well as further information about the controversial Swiss statement on HIV transmission risk from persons with HIV on HAART under certain conditions.

Critics of the previous reported efficacy of circumcision in African men challenged the utility of the intervention, because they were concerned about the durability of the protective effect. Followup data from Kisumu through 42 months indicated that the efficacy of male circumcision for preventing HIV infection in men was durable through this time point, and the author suggested that there may actually be a strengthening of this effect over time. (Rapporteur’s note: it appears that the confidence intervals for the estimates through 24 months and 42 months have overlapping confidence intervals, so the assertion of possible strengthening of protective effect should be interpreted with caution).

Data from the Orange Farm male circumcision trial were used to determine whether MC was associated with lower incidence of certain STIs. The results indicated that MC was associated with lower HPV prevalence and lower incidence of Trichomonas vaginalis, but were not associated with changes in the incidence of gonorrhea.

A macaque study of a combination emtricitabine/tenofovir gel, using repeated challenges with SHIV, suggested that this combination microbicide preparation holds promise for further evaluation: 7/8 control primates, but 0/6 treated primates, became infected after up to 20 challenges.

HIV testing was integrated into family planning clinics in Kenya was associated with an increase in the proportion of clients reporting ever testing for HIV, versus a control condition where clients were referred outside of the family planning clinic for testing. Integration in lower-level facilities, such as dispensaries, was reported to be the most cost-effective.

The organizers reserve the right to amend the programme.